Actavis Laboratories Ut Inc

General

Total Cases74
Active Cases2
Patents4
TypeOperating Company
Elite Ratings
--
--
--
--

Ratings

Experience
Grade
Trend
DCT
L5
C
PTAB
L5
E
CAFC
L5
E

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered
Case
Description
04/25/24
ACKNOWLEDGMENT OF RECEIPT of Defendant's trial exhibits. Acknowledgment filed by Adam Wyatt Poff on behalf of Defendant Tolmar Inc. (mpb) (Entered: 04/25/2024)
04/25/24
ACKNOWLEDGMENT OF RECEIPT of Defendant's trial exhibits. Acknowledgment filed by Adam Wyatt Poff on behalf of Defendant Tolmar Inc. (mpb) (Entered: 04/25/2024)
04/24/24
ACKNOWLEDGMENT OF RECEIPT of Plaintiffs' trial exhibits. Acknowledgment filed by Jack B. Blumenfeld on behalf of Plaintiffs. (mpb) (Entered: 04/24/2024)
04/24/24
ACKNOWLEDGMENT OF RECEIPT of Plaintiffs' trial exhibits. Acknowledgment filed by Jack B. Blumenfeld on behalf of Plaintiffs. (mpb) (Entered: 04/24/2024)
04/24/24
Letter to Adam Wyatt Poff, from the Clerk of the Court, regarding the return of Defendant's trial exhibits. (mpb) (Entered: 04/24/2024)
04/24/24
Letter to Adam Wyatt Poff, from the Clerk of the Court, regarding the return of Defendant's trial exhibits. (mpb) (Entered: 04/24/2024)
04/24/24
Letter to Jack B. Blumenfeld, from the Clerk of the Court, regarding the return of Plaintiffs' trial exhibits. (mpb) (Entered: 04/24/2024)
04/24/24
Letter to Jack B. Blumenfeld, from the Clerk of the Court, regarding the return of Plaintiffs' trial exhibits. (mpb) (Entered: 04/24/2024)
06/16/23
MANDATE of USCA as to 200 Notice of Appeal (Federal Circuit) filed by LTS Lohmann Therapie-Systeme AG, UCB, Inc., UCB Pharma GmbH. USCA Decision: AFFIRMED. (Attachments: # 1 Order Recalling Previous Mandate, # 2 Errata, # 3 Opinion, # 4 Judgment)(smg) (Entered: 06/16/2023)
05/26/23
MANDATE of USCA as to 200 Notice of Appeal (Federal Circuit) filed by LTS Lohmann Therapie-Systeme AG, UCB, Inc., UCB Pharma GmbH. USCA Decision: AFFIRMED. (Attachments: # 1 Opinion, # 2 Judgment)(smg) MANDATE RECALLED on 06/16/2023, SEE D.I. 206 (smg). (Entered: 05/26/2023)